3 198

Cited 0 times in

Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: A multicenter open-label single-arm trial in Korean patients

Authors
 Kyoung Heo  ;  Byung In Lee  ;  Sang Do Yi  ;  Yong Won Cho  ;  Dong Jin Shin  ;  Hong Ki Song  ;  Ok Joon Kim  ;  Sung-Pa Park  ;  Sung Eun Kim  ;  Sang Ho Kim  ;  Jun Hong Lee  ;  Kyu-Sik Kim  ;  Se-Jin Lee 
Citation
 SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, Vol.21(3) : 188-193, 2012 
Journal Title
 SEIZURE-EUROPEAN JOURNAL OF EPILEPSY 
ISSN
 1059-1311 
Issue Date
2012
MeSH
Adolescent ; Adult ; Aged ; Anticonvulsants/administration & dosage* ; Anticonvulsants/adverse effects ; Dose-Response Relationship, Drug ; Epilepsies, Partial/drug therapy* ; Female ; Humans ; Isoxazoles/administration & dosage* ; Isoxazoles/adverse effects ; Korea ; Male ; Middle Aged ; Seizures/drug therapy* ; Young Adult
Keywords
Antiepileptic drugs ; Zonisamide ; Epilepsy ; Partial seizures ; Open-label study ; Add-on therapy
Abstract
OBJECTIVE: To evaluate the efficacy and safety of adjunctive zonisamide (ZNS) therapy in Korean adults with uncontrolled partial epilepsy. METHODS: Study patients had an average of at least one seizure per 4-week (averaged over a 12-week historical baseline) despite the use of one to three antiepileptic drugs. The starting dose of ZNS was 100mg/day, and was increased to 200mg/day after 2weeks. During the 12-week maintenance period, the dose of ZNS was adjusted to 200-400mg/day based on the physicians' discretion. The global evaluation scale (GES) and quality of life (QOLIE-31) were also evaluated. RESULTS: A total of 121 patients were enrolled, of which 88 patients completed the study. The median percent reduction in weekly seizure frequency over the treatment period was 59.0%. The ≥50% and ≥75% responder rates were 57.3% and 38.5%, respectively. Seizure freedom over the treatment period was observed in 25 patients, but seizure freedom throughout the 16-week treatment period was attained in only 16 patients. On investigator's GES, 84 patients were considered improved, with 33 patients showing marked improvement. In QOLIE-31 scale, seizure worry improved significantly but emotional well-being deteriorated. Treatment-emergent adverse events (AEs) were reported in 80 patients. The most common AEs were dizziness (28.1%), somnolence (24.0%), anorexia (18.2%), headache (14.0%), nausea (13.2%), and weight loss (10.7%). Twenty-two patients discontinued the trial due to drug-related AEs. CONCLUSIONS: Our results suggest that adjunctive ZNS therapy for the treatment of refractory partial epilepsy, though efficacious, is associated with significant tolerability problems.
Full Text
http://www.sciencedirect.com/science/article/pii/S1059131111003177
DOI
22226572
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Byung In(이병인)
Heo, Kyoung(허경)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/91842
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse